DCR-LLY11 (LY3954068): An Investigational RNA Interference Therapeutic Targeting Tau for Neurodegenerative Diseases

I. Introduction to DCR-LLY11: An Investigational RNAi Therapeutic for Neurodegenerative Disease

A. Overview of DCR-LLY11 and its Nomenclature

DCR-LLY11 is an investigational therapeutic agent identified as a small interfering RNA (siRNA).[1] It is currently in the preclinical to early clinical (Phase 1) stages of development.[1] A critical aspect of understanding this compound is its nomenclature and association with other development codes. The "LLY" component in DCR-LLY11 strongly suggests its origin from the collaboration between Dicerna Pharmaceuticals and Eli Lilly and Company. Evidence indicates that DCR-LLY11 is the research or early developmental designation for the compound subsequently identified by Eli Lilly as LY3954068, which is an siRNA targeting Microtubule-Associated Protein Tau (MAPT) and is advancing through clinical trials for Alzheimer's disease.[2] This report will proceed based on the strong inference that DCR-LLY11 and LY3954068 represent the same therapeutic entity at different stages of its development lifecycle. This transition in nomenclature is a standard practice within the pharmaceutical industry as candidates progress from discovery to clinical phases; however, explicitly linking these designations is paramount for a comprehensive understanding of the drug's developmental trajectory and the aggregation of all relevant data.